132622-98-1Relevant articles and documents
INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
-
Paragraph 00319; 00320; 00324; 00326, (2019/02/17)
Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Chimeric amino acid analogues
-
, (2008/06/13)
A chimeric amino acid analogue is provided suitable for incorporating into peptides which compound is represented by Formula 1: STR1 where P1 is preferably an amine protecting agent, and P2 and P3 are preferably amine or guanidine protecting agents. X can be OH, halide, or preferably an activating group suitable for conjugating the compound of Formula 1 to a peptide by conventional means, and m and n are 0-1 and 0-2 respectively. Peptides containing the chimeric amino acid analog are provided and include a platelet-aggregation inhibitor represented by where Aaa1 is Gly or H, Cpdl is the compound of Formula 1 which has been deprotected and Aaa2 is a hydrophobic amino acid preferably Val.